Pathogenomix

Pathogenomix is a private molecular diagnostics and bioinformatics company focused on rapid pathogen identification using DNA sequencing. Its core commercial offering, Ripseq, is a cloud-based SaaS platform and curated microbial reference database that analyzes Sanger and targeted NGS data from pure or polymicrobial clinical samples, typically in under five minutes. The company is also developing Patho-Seq, an FDA-oriented assay workflow for clinical bacterial identification, which received FDA Breakthrough Device Designation in 2022 for use cases including sepsis and bacterial meningitis. Pathogenomix positions its technology as platform-agnostic and designed to improve identification accuracy versus conventional culture-based and less-curated sequence database approaches. Overall, the company operates at the intersection of infectious disease diagnostics, sequencing informatics, and clinical microbiology workflow enablement.